MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41523-020-00202-8

Медицинская библиотека · NPJ breast cancer · 2020

Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer.

Giardiello Daniele, Kramer Iris, Hooning Maartje J, Hauptmann Michael, Lips Esther H, Sawyer Elinor, Thompson Alastair M, de Munck Linda, Siesling Sabine, Wesseling Jelle, Steyerberg Ewout W, Schmidt Marjanka K

СтатьяПеревод пока не подготовлен

Аннотация

We aimed to assess contralateral breast cancer (CBC) risk in patients with ductal carcinoma in situ (DCIS) compared with invasive breast cancer (BC). Women diagnosed with DCIS (N = 28,003) or stage I-III BC (N = 275,836) between 1989 and 2017 were identified from the nationwide Netherlands Cancer Registry. Cumulative incidences were estimated, accounting for competing risks, and hazard ratios (HRs) for metachronous invasive CBC. To evaluate effects of adjuvant systemic therapy and screening, separate analyses were performed for stage I BC without adjuvant systemic therapy and by mode of first BC detection. Multivariable models including clinico-pathological and treatment data were created to assess CBC risk prediction performance in DCIS patients. The 10-year cumulative incidence of invasive CBC was 4.8% for DCIS patients (CBC = 1334). Invasive CBC risk was higher in DCIS patients compared with invasive BC overall (HR = 1.10, 95% confidence interval (CI) = 1.04-1.17), and lower compared with stage I BC without adjuvant systemic therapy (HR = 0.87; 95% CI = 0.82-0.92). In patients diagnosed ≥2011, the HR for invasive CBC was 1.38 (95% CI = 1.35-1.68) after screen-detected DCIS compared with screen-detected invasive BC, and was 2.14 (95% CI = 1.46-3.13) when not screen-detected. The C-index was 0.52 (95% CI = 0.50-0.54) for invasive CBC prediction in DCIS patients. In conclusion, CBC risks are low overall. DCIS patients had a slightly higher risk of invasive CBC compared with invasive BC, likely explained by the risk-reducing effect of (neo)adjuvant systemic therapy among BC patients. For support of clinical decision making more information is needed to differentiate CBC risks among DCIS patients.

Для цитирования: Giardiello Daniele, Kramer Iris, Hooning Maartje J, Hauptmann Michael, Lips Esther H, Sawyer Elinor, Thompson Alastair M, de Munck Linda, Siesling Sabine, Wesseling Jelle, Steyerberg Ewout W, Schmidt Marjanka K. Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer.. NPJ breast cancer. 2020. DOI: 10.1038/s41523-020-00202-8.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.